Compare Duke Energy Corp (DUK) vs Novavax Inc (NVAX) Price & Performance

Duke Energy (DUK) trades at $124.49, up 1.06% today, showing steady performance amid a bearish technical signal. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue growth has been stable, rising from $28.8B in 2022 to $32.24B in 2025, while net income margins improved to 15.78%. Recent news highlights storm recovery efforts and community investments, reflecting operational resilience.

The outlook remains positive with a consensus price target of $136.17, implying ~9% upside. Strengths include reliable dividend payments and earnings growth, but risks involve high debt levels and regulatory scrutiny. Analyst sentiment is mixed with 44% buy ratings, suggesting cautious optimism for long-term investors seeking utility exposure.

Novavax (NVAX) trades at $8.14, up 2.39% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $53 million in Q2 2026 but raised its full-year revenue outlook, driven by licensing milestones from its Sanofi partnership. Valuation ratios like P/E of 3.14 and EV/EBITDA of 1.72 appear low, yet negative profitability margins and cash flow challenges persist.

The outlook is mixed: analyst consensus is 74% buy with potential from partnerships, but risks include sustained losses, high debt, and competitive vaccine market pressure. Investors should weigh the low valuation against fundamental weaknesses and monitor execution on cost reductions and pipeline progress for upside catalysts.